Package Leaflet: Information for the User
RXULTI 0.25 mg film-coated tablets
RXULTI 0.5 mg film-coated tablets
RXULTI 1 mg film-coated tablets
RXULTI 2 mg film-coated tablets
RXULTI 3 mg film-coated tablets
RXULTI 4 mg film-coated tablets
brexpiprazole
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
RXULTI contains the active substance brexpiprazole, which belongs to a group of medicines called antipsychotics.
It is used to treat schizophrenia in adult and adolescent patients aged 13 years and older, a disease with symptoms such as hearing, seeing or feeling things that do not exist, distrust, incoherent speech and behavior, and emotional depression. People with this condition may also feel depressed, guilty, anxious, or tense.
RXULTI may help keep symptoms under control and prevent relapse during treatment.
Do not take RXULTI
Warnings and precautions
Tell your doctor immediately if
Tell your doctor or pharmacist before taking RXULTI, or during treatment if you have
Weight gain
This medication may cause significant weight gain, which can affect your health. Therefore, your doctor will regularly check your weight and blood fats.
Body temperature
While taking RXULTI, you should avoid overheating or dehydration. Do not overexert yourself and drink plenty of water.
Children and adolescents
Children under 13 years of age should not take this medication. Safety and efficacy in these patients have not been evaluated.
Other medicines and RXULTI
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
RXULTI may increase the effect of medications used to lower blood pressure. Make sure to tell your doctor if you are taking a medication to keep your blood pressure under control.
Taking RXULTI with some medications may mean that your doctor will need to change the dose of RXULTI or the other medications. It is especially important to mention the following medications to your doctor:
RXULTI with food and alcohol
RXULTI can be taken with or without food. Alcohol should be avoided, as it may affect how this medication works.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
RXULTI is not recommended during pregnancy. If you are of childbearing age, you should use effective contraception while taking RXULTI. Babies of mothers who take this medication during the last three months of pregnancy may have symptoms such as tremors, muscle stiffness, and/or weakness, drowsiness, restlessness, breathing problems, and difficulty feeding. If your baby has any of these symptoms, you should contact your doctor.
Talk to your doctor about the best way to feed your baby if you are taking RXULTI. Your doctor will consider the benefit of treatment for you and the benefit of breastfeeding for your baby.
Driving and using machines
There is a possibility that the medication may affect your ability to drive and use machines. Check that you do not feel dizzy or drowsy before starting to drive or operate machinery. Do not drive or use tools or machines until you know that this medication does not affect you negatively.
RXULTI contains lactose
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medication.
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The medication is usually administered in increasing doses as follows:
For adults:
For pediatric patients:
However, your doctor may prescribe a lower or higher dose up to a maximum of 4 mg once a day.
It does not matter if you take the medication with or without food.
If you were taking other medications for schizophrenia before starting treatment with RXULTI, your doctor will decide whether to gradually discontinue the other medication or immediately and how to adjust the dose of RXULTI. Your doctor will also inform you about how to act if you switch from RXULTI to other medications.
Patient with kidney problems
If you have kidney problems, your doctor may adjust the dose of this medication.
Patient with liver problems
If you have liver problems, your doctor may adjust the dose of this medication.
If you take more RXULTI than you should
If you have taken more RXULTI than the prescribed dose, contact your doctor or the nearest hospital immediately. Remember to take the medicine package with you so that it is clear what you have taken.
If you forget to take RXULTI
If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and take the next dose at the usual time. Do not take a double dose to make up for missed doses. If you forget two or more doses, consult your doctor.
If you stop taking RXULTI
If you stop taking this medication, you will lose its effects. Although you may feel better, do not change or stop your daily dose of RXULTI unless your doctor tells you to, as symptoms may recur.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
During treatment, you may have these serious side effects that require urgent medical attention.
Tell your doctor immediatelyif you have:
Other side effects
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Other side effects (frequency not known):
seizures,
Tell your doctor if you experience any of these behaviors; they will explain how to manage or reduce the symptoms.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and on the outer packaging after “EXP”. The expiry date refers to the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of RXULTI film-coated tablets
Each film-coated tablet contains 0.25 mg of brexpiprazole.
Each film-coated tablet contains 0.5 mg of brexpiprazole.
Each film-coated tablet contains 1 mg of brexpiprazole.
Each film-coated tablet contains 2 mg of brexpiprazole.
Each film-coated tablet contains 3 mg of brexpiprazole.
Each film-coated tablet contains 4 mg of brexpiprazole.
Tablet core:
Lactose monohydrate (see section 2 «RXULTI contains lactose»), corn starch, microcrystalline cellulose, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, magnesium stearate, purified water.
Tablet coating:
Hypromellose (E 464), talc (E 553b), titanium dioxide (E 171).
RXULTI 0.25 mg film-coated tablets
Iron oxide (E 172) (yellow, red, black)
RXULTI 0.5 mg film-coated tablets
Iron oxide (E 172) (yellow, red)
RXULTI 1 mg film-coated tablets
Iron oxide (E 172) (yellow)
RXULTI 2 mg film-coated tablets
Iron oxide (E 172) (yellow, black)
RXULTI 3 mg film-coated tablets
Iron oxide (E 172) (red, black)
Appearance and Package Contents
RXULTI 0.25 mg film-coated tablets
Light brown, round, 6 mm in diameter, smooth, convex and beveled edge, engraved with BRX and 0.25 on one side.
RXULTI 0.5 mg film-coated tablets
Light orange, round, 6 mm in diameter, smooth, convex and beveled edge, engraved with BRX and 0.5 on one side.
RXULTI 1 mg film-coated tablets
Light yellow, round, 6 mm in diameter, smooth, convex and beveled edge, engraved with BRX and 1 on one side.
RXULTI 2 mg film-coated tablets
Light green, round, 6 mm in diameter, smooth, convex and beveled edge, engraved with BRX and 2 on one side.
RXULTI 3 mg film-coated tablets
Light purple, round, 6 mm in diameter, smooth, convex and beveled edge, engraved with BRX and 3 on one side.
RXULTI 4 mg film-coated tablets
White, round, 6 mm in diameter, smooth, convex and beveled edge, engraved with BRX and 4 on one side.
RXULTI tablets are supplied in an aluminum/PVC blister pack containing 10, 28 or 56 film-coated tablets.
Not all pack sizes may be marketed.
Marketing Authorization Holder
Otsuka Pharmaceutical Netherlands B.V.
Herikerbergweg 292
1101 CT, Amsterdam
Netherlands
Manufacturer
Elaiapharm
2881 Route des Crêtes, Z.I. Les Bouillides-Sophia Antipolis,
06560 Valbonne
France
Ottiliavej 9
2500 Valby
Denmark
For further information about this medicinal product, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien Lundbeck S.A./N.V. Tel: +32 2 535 79 79 Tel: +32 2 340 2828 | Lietuva
Tel: +45 36301311 |
Luxembourg/Luxemburg Lundbeck S.A. Tel: +32 2 535 79 79 Tel: +32 2 340 2828 | |
Ceská republika Lundbeck Ceská republika s.r.o. Tel: +420 225 275 600 | Magyarország Lundbeck Hungaria Kft. Tel: +36 1 4369980 |
Danmark Otsuka Pharma Scandinavia AB Tel: +46 8 54528660 | Malta
Tel: +45 36301311 |
Deutschland Otsuka Pharma GmbH Tel: +49 69 1700860 | Nederland Lundbeck B.V. Tel: +31 20 697 1901 |
Eesti
Tel: +45 36301311 | Norge Otsuka Pharma Scandinavia AB Tel: +46 8 54528660 |
Ελλáδα Lundbeck Hellas S.A. Τηλ: +30 210 610 5036 | Österreich Lundbeck Austria GmbH Tel: +43 1 253 621 6033 |
España Otsuka Pharmaceutical S.A. Tel: +34 93 208 10 20 | Polska Lundbeck Poland Sp. z o. o. Tel.: +48 22 626 93 00 |
France Otsuka Pharmaceutical France SAS Tél: +33 (0)1 47 08 00 00 | Portugal Lundbeck Portugal – Produtos Farmacêuticos, Unipessoal Lda. Tel: +351 21 00 45 900 |
Hrvatska Lundbeck Croatia d.o.o. Tel.: +385 1 644 82 63 Tel.: +385 1 3649 210 | România Lundbeck Romania SRL Tel: +40 21319 88 26 |
Ireland Lundbeck (Ireland) Limited Tel: +353 1 468 9800 | Slovenija Lundbeck Pharma d.o.o. Tel.: +386 2 229 4500 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Lundbeck Slovensko s.r.o. Tel: +421 2 5341 42 18 |
Italia Otsuka Pharmaceutical Italy S.r.l. Tel: +39 02 00 63 27 10 | Suomi/Finland Otsuka Pharma Scandinavia AB Tel: +46 8 54528660 |
Κúπρος Lundbeck Hellas A.E Τηλ.: +357 22490305 | Sverige Otsuka Pharma Scandinavia AB Tel: +46 8 54528660 |
Latvija
Tel: +45 36301311 |
Date of the last revision of this leaflet:
Other sources of information
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.